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Abstract: Tumor mass is constituted by a heterogeneous group of cells, among which a key role is played
by the cancer stem cells (CSCs), possessing high regenerative properties. CSCs directly metastasize to bone,
since bone microenvironment represents a fertile environment that protects CSCs against the immune
system, andmaintains their properties and plasticity. CSCs can migrate from the primary tumor to the
bone marrow (BM), due to their capacity to perform the epithelial-to-mesenchymal transition. Once in
BM, they can also perform the mesenchymal-to-epithelial transition, allowing them to proliferate and
initiate bone lesions. Another factor explaining the osteotropism of CSCs is their ability to recognize
chemokine gradients toward BM, through the CXCL12–CXCR4 axis, also known to be involved in tumor
metastasis to other organs. Moreover, the expression of CXCR4 is associated with the maintenance of
CSCs’ stemness, and CXCL12 expression by osteoblasts attracts CSCs to the BM niches. CSCs localize in
the pre-metastatic niches, which are anatomically distinct regions within the tumor microenvironment
and govern the metastatic progression. According to the stimuli received in the niches, CSCs can remain
dormant for long time or outgrow from dormancy and create bone lesions. This review resumes different
aspects of the CSCs’ bone metastastic process and discusses available treatments to target CSCs.
Keywords: bone metastases; cancer stem cells; osteotropism
1. Introduction
Due to advances in early diagnosis and cancer treatments, the survival of cancer patients has
improved over the last two decades. As a negative consequence, the probability of cancer patients
developing metastasis has increased. Bone is one of the most common sites of metastases, since
some tumors show a marked osteotropism [1]. The propensity of some tumor to metastasize to bone
depends on many factors such as the expression of adhesive molecules and bone markers on the
surface of tumor cells (i.e., vitamin D receptor, RANKL, RUNX2, ↵V 3, etc.) [2,3]; the expression
of a set of genes associated with bone metastases [4–21]; and the capability of performing the
epithelial–mesenchymal transition (EMT) of carcinomas [2,3,22–61]. In the bone microenvironment,
cancer cells disrupt the physiological balance between bone resorption and formation, leading to
lesions. Indeed, the interaction between cancer and bone cells causes the disarrangement of the bone
matrix, disrupting the bone micro-architecture and impairing the bone function [62–64].
Literature reports that bone marrow (BM) is an appealing site for tumor cells and particularly
for cancer stem cells (CSCs), which are able to resist treatments, such as chemo-radiotherapy. Indeed,
once CSCs reach BM, they can remain dormant or cause bone metastases, long after the primary tumor
has been surgically removed from patients [65,66]. CSCs have been isolated from many tumors and
have been characterised for the expression of markers according to their different origin: the most
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representative markers with their functions are reported in Table 1. In this work, we focus on the
dialogue among CSCs, bone and the tumor microenvironment, and the consequent formation of
bone metastases.
Table 1. Cancer stem cell markers.
Marker Family Function Tumors Effects References
CD44 Cell surface HA-bindingglycoprotein
Tissue remodeling,
adhesion of
cell-matrix, and cell
migration
Breast, Prostate, Liver
Aggressive phenotype,
Tumor progression,
Stemness phenotype,
Bone metastasis
[4,67–70]
E-cadherin Type I transmembrane protein
Maintain normal cell
structure, cell
polarity and integrity
Prostate, Breast, Brain
Stemness gene
expression, Tumor
progression, Invasion
and metastasis,
Theraphetic resistance
[71–73]
CD166
Immunoglobulin superfamily
of cell adhesion molecules
(Ig-CAMs)
Intercellular
adhesion, leukocyte
extravasation, T cell
activation and
proliferation, and
stabilization of the
immunological
synapse
Lung Cellular proliferation,Stemness phenotype [74,75]
EpCAM Epithelial cell adhesionmolecule
Wnt-beta-catenin
signaling Liver, Prostate
Tumor progression,
Invasion and metastasis,
Therapheutic resistance
[76,77]
ABCB5 ATP-binding cassettesub-family B
Drug efflux
transporter
Melanoma, Breast,
Colorectal, Liver
Tumor progression,
recurrence, Therapeutic
resistance, Metastasis,
Invasion
[78–82]
ABCG2 ATP-binding cassette (ABC) Drug effluxtransporter Breast, Prostate, Liver
Stem cell phenotype,
Proliferation, Migration,
Therapeutic Resistance
[83–85]
ALDH Detoxifying enzyme Proliferation
Breast, Lung, Brain,
Colon, Liver, Prostate,
Bladder, Ovarian,
Renal
Tumor progression,
Self-renewal capacity, [86–92]
CD133 Transmembrane protein
Proliferation,
differentiation
and self-renewal
Gastric, Lung, Liver,
Colon, Renal, Prostate,
Pancreatic
Tumor progression,
Stemness gene
expression, Bone
metastasis
[20,93–97]
CD13 Membrane glycoprotein Aminopeptidase N Liver Invasion, Angiogenesis,Proliferation [98,99]
CD90 Glycosylphosphatidylinositol-anchored glycoprotein
Cell-cell and
cell-matrix
interactions
Liver, Breast, Lung Invasion, Tumorprogression [100–102]
CD105
Type I membrane
glycoprotein, TGF beta
receptor complex
Angiogenesis,
Mesenchymal Stem
cell marker
Renal, Breast, Liver
Initiating metastatic
process, Stemness gene
expression, Migration,
Bone metastasis
[50,103–106]
2. Cancer Stem Cells (CSCs) Have a Pivotal Role in Tumor Heterogeneity
Tumor mass is constituted by a heterogeneous group of cells responsible for its formation and
maintenance. This cell heterogeneity of many cancer types derives from a hierarchical organization
that resembles one of the tissue of origin [80,107]. According to the hierarchical model, in the primary
tumor at the apex of the hierarchy there are cells showing stem cell-like properties, the so-called CSCs.
The phenotype and function of cancer CSCs appear to be equivalent to normal stem cells, but they
harbour oncogenic mutations. CSCs possess high regenerative properties: self-renewal, and the ability
to modify the response to stress conditions and thus survive in hostile conditions [108,109]. Date
in literature, deriving from mouse models, provides genetic evidence that primary brain, colon and
skin cancers comply with the hierarchical organization [110,111]. Also, clinical data confirm this
hierarchical model; indeed, cell populations isolated from primary tumors using stem-cell marker
genes can generate tumors when transplanted into mice [112–114]. Stem-cell properties are mainly
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maintained by four known transcription factors, such as octamer-binding transcription factor 4 (Oct4),
Nanog, SRY-Box 2 (Sox2) and Kruppel-like factor 4 (Klf4) [115–118] and by different growth factors,
such as epidermal growth factor (EGF) and fibroblast grow factor (FGF) [119,120]. To maintain the
pluripotent stem-cell state Oct4 and Sox2 bind together forming a heterodimer, before linking to
different sites on Klf4. Then, the Oct4/Sox2/Klf4 complex binds Nanog promoter [121]. Among these
transcription factors, Oct4 is the main regulator, indeed the knock out of Oct4 expression dramatically
reduces Sox2 and Nanog expression [122]. Moreover, Oct4 controls its expression: its increase inhibits
the transcription of the Nanog gene and thus reduces Oct4 expression [123]. This work demonstrates
that a delicate balance among these transcription factors influence the stem-cell phenotype [124].
Tumor heterogeneity also depends on the presence of various genetically related subclones,
which compete with each other thanks to their different characteristics and evolve during tumor
progression, allowing the acquisition of genetic instability and somatic mutations that favour one tumor
clone over others [125–127]. Genome-sequencing studies have shownmore similarities than differences
between primary tumors and metastasis, suggesting that most of the genetic mutations required for
metastasis are already present in the primary tumors [128,129]. Lastly, the environment where cancer
cells reside activates epigenetic mechanisms, such as epigenetic reprogramming, which induces the
stem-cell state [130].
3. EMT: A Key Step in CSC-induced Bone Metastases
EMT is a crucial step in tumor progression and has an important role during cancer invasion and
metastasis. The importance of EMT for the induction of stem characteristics has been demonstrated in
different carcinomas [131,132]. In immortalized human mammary epithelial cells, induction of an EMT
results in the acquisition of mesenchymal traits and in the expression of stem-cell markers [133]. Some
recent studies in transgenic mouse models showed that CSCs undergo EMT and initiate a tumor
process [134,135]. These data were confirmed in clinical studies, showing the presence of tumor
cells with CSCs capabilities in BM of breast cancer patients [136]. CSCs exist both in epithelial
and mesenchymal states [133,137]: they perform EMT and express epithelial markers in order to
promote migration from the primary tumor to secondary organ, such as BM, where they perform
a mesenchymal-epithelial transition (MET), expressing markers that allow them to proliferate and
initiate secondary lesions. The EMT transition is also a mechanism involved in bone metastasis
formation [138]. Different studies reported that growth factors, such as transforming growth factor- 
(TGF ) and insulin-like growth factor (IGF), produced or released from the bone microenvironment,
are potent effectors of EMT and can stimulate the formation of bone metastasis [139–141].
CD44 is an adhesion molecule that binds to the extracellular matrix through hyaluronan [142],
increases the expression of the receptor activator of nuclear factor (NF)-B ligand (RANKL) in stromal
cells of BM, and promotes osteoclastogenesis [143,144]. CD44 has been recognized as one of the cell
surface markers of CSCs in different tumors [145,146], and its expression is linked to an enhanced
ability of CSCs to metastasize [147]. For instance, CD44 is significantly expressed by breast cancer cells,
where it promotes invasion and adhesion to BM [148], and breast CSCs were initially identified as
CD44+CD24  cells [70,149]. Clinical studies suggested a positive correlation between CD44 expression
and bone metastasis [136,150]. Hiraga et al. demonstrated that breast CSCs’ migration, invasion and
their ability to form bone metastasis in nude mice were inhibited by the down regulation of CD44 [151].
In a human-in mouse model, we previously showed that breast CD44+CD24  CSCs were present in
the primary tumor, with a mesenchymal phenotype allowing them to migrate towards bone. After
reaching the bone, in order to proliferate they performed a MET transition acquiring an epithelial
phenotype; indeed, we detected CD44 CD24+ cells in bone. Once CD44 CD24+ cells collected
by bone lesions were re-injected in mice, they formed new tumor masses, with a heterogeneous
population, constituted mainly by CD44+CD24  cells [4]. Our data confirm a previously reported
work of Liu et al. demonstrating a transition between epithelial and mesenchymal states of breast
CSCs [5]. Also, Chaffer et al. demonstrated that CD44low breast-cancer cells can spontaneously
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convert into CD44high CSCs both in vitro and in vivo [130]. The capability of the breast metastatic
CD44 CD24+ cells isolated from bone to generate new heterogeneous tumors with a high percentage
of CD44+CD24  CSCs is consistent with a phenotypic plasticity of these cells, that allow metastatic
cells to regain a tumor-initiating capacity. This transition between different states observed in CSCs
can be considered a stochastic transition, and can be explained by the quantitative Markov model of
cell-state interconversion, where any subpopulation of cancer cells returns to equilibrium, with the
phenotypic proportion of the primary tumor over time. Thus, by contrast with the hierarchical model
and according to the stochastic one, breast cancers can be constituted by discrete populations that
randomly perform transitions between states without increasing their proliferation rate, simply to
reach a progressive equilibrium proportion [6,7].
4. Role of CXCL12–CXCR4 Axis in CSC-Tumor Microenvironmet Crosstalk
CSCs seem to be quite pleiotropic in the expression of receptors in response to different
microenvironmental stimulation, and thus they can modify their expressions in response to the level
of ligand and move towards a secondary organ according to a chemotactic gradient. One of the main
chemotactic stimulus involved in the regulation of trafficking of normal and CSCs is represented by the
C–X–C motif chemokine 12 ligand (CXCL12) and C–X–C chemokine receptor type 4 (CXCR4) axis [8].
Indeed, CXCR4 is expressed not only in normal stem cells in different organs, but also in several
tumors [9]. The CXCR4–CXCL12 axis is involved in cancer-cell-tumor microenvironment interactions
and it is one of the mechanism involved in bone metastases formation [10]. Indeed, bone-seeking
breast cancer cells express high levels of CXCR4, which is associated to cancer-cell stemness [11,136].
CXCL12 is highly expressed in bone, lymph nodes and lungs, CSCs expressing CXCR4 are
attracted by these organs [12,13]. CSCs recognize chemokine gradients toward BM, like the gradient
followed by hematopoietic stem cells (HSCs) and leukocytes to migrate to the bone [14]. Indeed,
both mesenchymal stromal cells and osteoblasts (OBs), in BM, constitutively express CXCL12 [15],
and they help the entrance of CSCs expressing CXCR4 into the bone microenvironment. In non-small
cell lung cancer (NSCLC), the expression of the CXCR4 receptor has been associated with the
maintenance of stemness of chemoresistant CSCs both in cell lines and primary tumors [16,17].
CXCL12 has been proven to induce EMT in different tumors [18,19], such as NSCLC, where a subset
of CD133+CXCR4+ EpCAM  CSCs could be directly generated through EMT activation [17]. Indeed,
we demonstrated in a humanized murine model that CD133+CXCR4+ EpCAM  CSCs were endowed
with an enhanced bone tropism [20]. The ability of CD133+CXCR4+ CSCs to originate frank
metastases when injected in humanized mice implanted with human bone stresses the prominent
relevance of a conductive tumor microenvironment (with a pre-metastatic niche) to support tumor
metastasis [139,140]. The over-expression of CXCR4 and CXCR7 by breast and prostate cancer cells
increases their vascular ability and bone colonization in mouse models [21,152]. CXCR4 is also essential
for maintenance of renal cell carcinoma-initiating cells [153].
5. Tumor Microenvironment and CSCs
The tumor microenvironment is composed of non-malignant cells such as endothelial cells,
fibroblasts, immune cells and a non-cellular matrix. Both the cellular and non-cellular components
form the tumor stroma, which dramatically changes during the tumor progression, influencing tumor
growth and chemoresistance [154,155]. The tumor microenvironment releases different factors, it is
able to protect CSCs against the immune system, and it maintains CSCs’ properties and plasticity [156].
Furthermore, the primary tumor stroma also seems to select for organ-specific seeding traits.
For example, cancer-associated fibroblasts (CAFs), in breast-cancer stroma, produce CXCL12 and IGF-1,
which select Src hyperactive cancer clones, and promote bone metastases [157,158]; in NSCLC, stimuli
from CAFs in the tumor microenvironment could dictate de novo creation of the CD133+CXCR4+
CSCs subset, directly linked to EMT induction with the acquisition of increased dissemination [20].
In colorectal cancer, CAF release hepatocyte growth factor, which stimulates the self-renewal of CSCs
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through a  -catenin-dependent mechanism [159] and promotes the reprogramming of colorectal
cancer progenitors into CSCs [160]. Moreover, CAFs secrete specific cytokines and chemokines
upon chemotherapy treatment, such as IL-17A, that stimulates colorectal CSC self-renewal and
invasion [161]. This last observation indicates that chemotherapy induces a remodelling of the tumor
microenvironment and thus contributes to promote CSC proliferation [162].
6. CSCs’ Dormancy in the Niche
CSCs have the capability to grow as spheres, and thus they can easily enter and disseminate in
blood circulation. Once they have reached a secondary organ, such as BM, they can remain silent
or undergo asymmetric division, allowing the maintenance of the CSC population as well as the
expansion of differentiated cancer cells, which represent the full spectrum of the original tumor
heterogeneity and maintain secondary lesions [163–165] (Figure 1).
 
Figure 1. Cancer stem cells’ (CSCs) steps toward bone metastasis. At the primary tumor, cancer
cells grow and can perform epithelial-to-mesenchymal transition (EMT), which confers them with
invasive properties and consequent intravasation in the circulation. Once they have reached the
BM microvasculature, CSCs can undergo senescence and cell death, or colonize the BM, regaining
their original epithelial phenotype through a mesenchimal-to-epithelial transition (MET). Then CSCs
can enter into a quiescent state (dormancy) in the BM niches, where osteoblasts (OBs) contribute
to dormancy, or they can proliferate, releasing factors activating osteoclasts (OCs) and forming
bone lesions.
CSCs metastasize to the BM, localizing in HSC niches, creating the so-called pre-metastatic niches,
which are anatomically distinct regions within the tumor microenvironment that govern metastatic
progression [166,167]. OBs are constituent of the niches and maintain HSC by secreting growth
factors such as stem-cell factor (SCF), CXCL12 and angiopoietin [168,169]. The importance of OBs
in supporting the metastatic niche has been demonstrated in prostate cancer, where in an in vivo
model the ablation of OBs significantly decreased the presence of disseminated cancer cells in the
BM [170]. Compelling evidence from Shiozawa et al. reported that disseminated prostate cancer cells
compete with HSC for niche support, where they can be remobilised in the circulation by the same
molecules that induce HSC [170]. OBs also control long-term dormancy and support the cell survival
of CSCs [171]: they exert a protective role for CSCs from the immune system, preserve their phenotypic
plasticity, and promote their dormancy or metastatic potential.
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Dormancy depends on different exogenous factors released by several BM stromal cells and
the matrix: for instance, OBs express cadherins which allow bonds with CSCs [172] and the
bone matrix [173]; annexin II expressed by OBs and endothelial cells plays a critical role in niche
selection [174]. OBs also secrete factors such as growth arrest specific 6 (GAS6), which binds to
the receptor tyrosine kinase AXL, activating it and thus promoting tumor cell dormancy [175].
Osteopontin induces mesenchymal stem cells in the tumor microenvironment to differentiate into
CAFs, which promote cancer growth and can be educated to release periostin in the metastatic
microenvironment [22,23]. Periostin is a critical factor promoting the stemness of CSCs and the CSCs’
niche via the IL-6/STAT3 signaling pathway [23,24], and the expression of IL-6 has also been associated
with the dormancy phenotype. Recent data reported that dormancy could also be an intrinsic feature
of a subpopulation of cancer cells that have arisen in a hypoxic microenvironment, which can remain
dormant initially and later on be responsible for disease relapse [25].
Perivascular niches are important for the maintenance of both HSCs [26] and CSCs [27].
Indeed, endothelial cells in the mature microvascolature express thrombospondin-1 and other factors
which maintain breast CSCs dormant [28]. On the other hand, endothelial cells in the sprouting
neovasculature produce tenascin C, fibronectin and other factors that induce the formation of different
perivascular niches and accelerate CSCs’ outgrowth [28]. Thus, it is likely that the dynamic of the niche
components, rather than spatial localization, regulates the quiescence or the proliferation of CSCs.
7. Outgrowth from Dormancy
CSC-niche crosstalk is fundamental for outgrowth from dormancy and is affected by the bone
microenvironment, which can remove crucial signals able to maintain cells dormant in the metastastic
niche. Indeed, the balance between dormancy and CSCs’ re-activation depends on microenvironmental
factors, which contribute to the outgrowth from the dormancy of CSCs, and their interactions with
stromal cells in bone [29]. For instance, stromal cells can be activated by dormant breast CSCs
to release niche extracellular matrix components, such as Periostin and Tenascin C, which in turn
activate the crucial stem-cell signalling pathways such as Wnt, Nanog and Oct4, fostering proliferation
and outgrowth from the dormancy of CSCs [23,172]. In the tumor microenvironment, fibronectin
and type I collagen were reported to stimulate ERK/MAPK and Src driven proliferation, shifting
tumor cells from dormant to proliferative via  1-integrin stimulation [30–32]. Specifically, in the
BM, multiple myeloma cell dormancy has been described as a reversible state, which is switched on
by OBs and switched off by OCs remodelling the endosteal niche [171]. Indeed, OCs remodel the
surface of the endosteal niche releasing dormant myeloma cells and favouring their outgrowth from
dormancy [171]. A similar mechanism of OC-mediated escape from dormancy has been reported in
breast-cancer cells that aberrantly express the vascular cell-adhesion molecule 1 (VCAM-1), recruit
↵4 1 OC precursors by engaging in VCAM-1/↵4 1 binding to increase Oct activity, and stimulate
tumor growth [166]. The physiological bone remodelling, through the release of different molecules,
provides a fertile soil for the growth of tumor cells, such as TGF- , IGF I and II, platelet-derived
growth factor (PDGF), fibroblast growth factor (FGF), and bone morphogenetic proteins (BMPs) [33,34].
It is also responsible for the high extracellular Ca2+ concentration, which can bind to calcium-sensing
receptors and stimulate PTH-related peptide (PTHrP) in re-activated CSCs, promoting tumor-cell
proliferation and survival [35,36]. Moreover, physical factors such as acid pH, hypoxia and high
extracellular calcium concentration contribute to CSCs’ awakening and, thus, metastasis formation in
breast cancer [166]. Proliferating tumor cells can secrete prostaglandins, PTH, activated vitamin D, IL-6
and tumor necrosis factor (TNF), leading to an increase in RANKL expression on OBs and BM stromal
cells [34], which stimulates OC numbers, survival and activity. Among the factors and pathways
that regulate the progression of CSCs to bone metastases there are also VCAM1, tumor-induced OC
miRNAs and Jagged1 [37–39]. In particular, Jagged1 is a ligand of Notch, one of the most important
downstream mediators of the pro-metastatic TGF- , that directly activates OC differentiation and
promotes tumor growth, stimulating IL-6 production by OBs [40].
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Recent data reported that tumor-derived microvescicles, such as exosomes, are also involved in
metastasis formation. They contain integrins, which mediate the homing of metastastic cells to specific
secondary organs [41], and they can transfer oncogenic proteins and nucleic acids, modulating the fate
of tumor cells and target organs [42–44].
8. Targeting CSCs to Block Bone-Metastasis Formation
Since CSCs play a fundamental role in promoting bone metastases, they represent a target for
novel or combined anti-cancer therapies. Indeed, targeting and eliminating CSCs is an approach
largely envisioned to avoid cancer dissemination, disease relapse and thus the development of bone
metastases. Methods to target CSCs may be represented by drugs inhibiting CSC-specific signalling
pathways, compounds targeting alterations in CSC metabolism, methods to induce differentiation or
a loss of stemness, and immunotherapy directed at CSC markers [45].
Different groups have focused their efforts on studies aimed at discovering new targeted CSCs
therapies. For instance, BR-DIM, a cruciferous vegetable metabolite added to the prostate cancer cell
cultures, was proved to inhibit self-renewal ability of CSCs [46], suggesting that this treatment may
induce CSC terminal differentiation and prevent therapeutic resistance.
Another successful approach has recently been reported by Cuyas et al. for aggressive forms
of breast cancer: they showed that in breast cancer, a dysregulation of the OPG/RANK/RANKL
signalling axis is present and is associated with the presence of CSCs’ highly expressing RANK,
residing in the pre-metastatic niche and able to initiate metastasis including bone lesions [47–49].
Moreover, in these tumors, bone metastases are also promoted by the low levels of OPG and high
levels of RANKL. It is known that treatment with denosumab, an anti-RANKL antibody, reduces
the mammosphere-forming ability in BRCA1-mutated epithelial cells, in triple negative and in
HER2-overexpressing breast-cancer cells, supporting the notion that tumor and cancer initiating
cells have hyperactive RANKL signalling in primary and metastatic sites such as bone. Moreover,
the combination with metformin, an anti-diabetic molecule, with denosumab, showed a synergistic
action of the two drugs in reducing breast CSCs [49].
Our group showed that renal CSCs expressing CD105 and c-MET can directly form osteolytic
bone lesions, and a selective c-MET inhibitor treatment abrogated bone metastases’ development.
Those data suggest that c-MET expression on renal CSCs drives renal cancer progression to bone,
thus HGF/c-MET signalling is relevant in the metastatic bone process induced by these CSCs [50].
Based on previous studies on breast cancer reporting that CD44+ CSCs expressed also the oncogene
c-MET [114], and its inhibition blocked bone metastases from breast cancer [51], we tested a selective
c-MET inhibitor. We demonstrated it was able to inhibit the stimulatory activity of renal CSCs on
OCs, likely interfering with paracrine factors produced by CSCs, which promoted OC bone resorption.
On the other hand, we observed that it stimulated OBs, suggesting us to conclude that this inhibitor
exerted both effects on bone cells and CSCs.
In addition, inhibitors of CXCR4, such as CTCE-9908, a small peptide analogue of SDF-1, have
been demonstrated to be effective in preventing metastatic dissemination in different cancer models
such as breast, oesophageal and prostate [52–55], by acting both on CSCs and on proliferating tumor
cells. In particular in NSCLC, CXCR4 targeting was able to counteract the chemotherapy-induced
metastatic spread of chemoresistant fractions of CD133+CXCR4+ CSCs, pointing at combination
therapy with CXCR4 inhibitor as an attractive novel strategy to improve neo-adjuvant and adjuvant
therapy for these tumors [20]. In a prostate-cancer model, the use of a neutralizing antibody to CXCR4
also reduced the growth of prostate cancer cells injected intra-tibia and the subsequent formation of
bone metastases [13].
Other possible pathways of interest include Akt activation and Erk signalling [8,56], which may
be up-regulated in CSCs in comparison with the bulk-tumor population and responsible for enhanced
CSC survival. In addition, new small molecule inhibitors are under development; they target
signalling pathways and transcription factors prevalent in CSCs but not in normal cells [57]. Moreover,
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CSC-targeted interventions, combination therapies could also target simultaneously several types of
cells and pathways, such as bulk-tumor cells, CSCs in the niche, tumor-associated macrophages, tumor
microenvironment or the adaptive immune system [45].
Lastly, CSC markers can be considered as immune targets [58], but examination of CSC markers
is needed since some markers may identify both normal stem cells and CSCs, such as Trop2 and ↵6
integrin [59,60], causing adverse events in clinical trials.
9. Conclusions
The importance of targeting CSCs to avoid tumor metastases has emerged as a prominent
concern. Thus, an integrated approach with the development of ex vivo and in vivo models should
lead to further characterization of the CSCs. High-resolution imaging technology together with the
identification of stromal markers will improve our understanding of CSCs in order to more accurately
recapitulate the niche of tumorigenic cells and address novel mechanisms that operate in CSCs,
especially during tumor progression. Moreover, continuous investigation of CSC markers is needed,
since some markers may identify both normal stem cells and CSCs and cause adverse events in clinical
trials. Lastly, many efforts are also advocated on the discovery of novel procedures to isolate, identify
and enrich for CSCs, with the final goal of monitoring the disease in terms of prevention of tumor
progression and resistance to treatments.
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